Human Albumin

containing a recombinant fusion protein of the long-acting human serum albumin (HSA) and human granulocyte derived colony stimulating factor (G-CSF), units derived Granulopoese having potential activity. G-CSF, a naturally occurring cytokine that stimulates the production of granulocytes and stem cells in the bone marrow and their release into the blood; it also stimulates differentiation, function and survival of neutrophil precursors and mature neutrophils. Albumin fusion, increased serum half-life and bioavailability of the G-CSF part promote this fusion protein.

5-Aminotetrazole

Product name:5-Aminotetrazole
CAS:     4418-61-5
Molecular Formula:CH3N5
Formula Weight:85.07
Description:
Melting point:200-206 ºC
Boiling point:360.4 °C at 760 mmHg
Flash Point:199.1 °C
Density:1.711 g/cm³
Chemical property:white crystals
Use:as an intermediate in the organic synthesis.
Storage:In ventilate,cool and dry places.

Sodium 3-nitrobenzenesulfonate for sale

Product name:Sodium 3-nitrobenzenesulfonate
CAS:127-68-4
Molecular Formula:C6H4NNaO5S
Formula Weight:     225.15
Description:
Melting point:52 - 54 C 
Flash Point:215 - 219 C 
Density:1.637g/cm³
Chemical property:off-white to yellow powder
Use:mainly for the reduction of dyes color ink knows when to stop. cook printing dye and dyeing color-reactive stabilizers during rolling, as intarsia anaglyph, repair with dyes for colored fabrics, wire and the reduction of the water used intelligently cryoprotectant. 

What is Epalrestat

Diabetic neuropathy is the most common long-term complications in patients with diabetes mellitus, with a prevalence of 60-70% in the United States. The treatment options include antidepressants, anticonvulsants, tramadol and capsaicin. These funds are modestly effective in relieving symptoms, but they do not affect the underlying disease must still slow the progression of the disease. Epalrestat is an inhibitor of aldose reductase, which is approved in Japan for the improvement of subjective symptoms neuropathy, abnormal sense of vibration, and abnormal changes in the heart rate in diabetic peripheral neuropathy. Unlike current treatment options for diabetic neuropathy can affect epalrestat or delay the progression of the underlying disease. The results of experimental studies show that epalrestat sorbitol accumulation in the sciatic nerve is decreased, red blood cells and ocular tissue in animals and humans in red blood cells. The data from six clinical trials were evaluated and it was determined that epalrestat 50 mg 3 times / day may improve motor and sensory nerve conduction velocity and subjective symptoms such as neuropathy at baseline and compared to placebo. Epalrestat is well tolerated and the most commonly reported side effects include increases in liver enzymes and gastrointestinal-related events, such as nausea and vomiting. Epalrestat can serve as a new therapeutic option to prevent or slow the progression of diabetic neuropathy. The long-term comparative studies in different patient groups are needed for clinical use.

Anthralin

Product name:Anthralin
CAS:     1143-38-0
Molecular Formula:     C14H10O3
Formula Weight:     226.23
Description:
 Anthralin (USAN and former BAN) is a Hydroxyanthrone, anthracene derivative, medicine applied to the skin of people with psoriasis. It is available as creams, ointment or pastes in 0.1 to 2% strengths (Drithocreme, Dithrocream, Zithranol-RR, Micanol, Psorlin, Dritho-Scalp, Anthraforte, Anthranol and Anthrascalp). The terms dithranol and anthralin are sometimes used synonymously.

Human Pulmonary Alveolar Epithelial Cells

Product name:HPAEpiC(Human Pulmonary Alveolar Epithelial Cells)
Specifications:1 x 106 cells, 1 ml

Type:Pulmonary Cell System

Product description:
HPAEpiC are isolated from human lung tissue. HPAEpiC are cryopreserved at primary culture and delivered frozen. HPAEpiC are characterized by immunofluorescent method with antibodies CK-18, -19, and vimentin. HPAEpiC are negative for HIV-1, HBV, HCV, mycoplasma, bacteria, yeast and fungi.

American Institutes of Health AIDS research funding to abandon the quota

Over the past 20 years, the US National Institutes of Health (NIH) has funded AIDS research were fixed in 10% of the overall budget. However, this year NIH funding will reduce this level. The latest fund funding success rates reflects a motivation to abandon the reserved quota: In many organizations, access to AIDS research funding than non-AIDS research funding much easier, and this shows that government officials are doing everything possible to find the money to spend Method.

In the early 1990s, when the AIDS epidemic is still in the stage of the outbreak, the US Congress and NIH agreed annually section NIH AIDS research budget devoted to stabilizing at about 10%. However, since then, racking their brains to find some agencies spend AIDS funding approaches, sometimes even extend the definition of AIDS research, or relax standards. Recently, some members of Congress questioned this: when AIDS deaths in the United States have begun to decline, to provide special treatment for this disease is still make sense?

Last year, NIH Dean Francis Collins announced that AIDS funding agency will focus more directly to steering vaccines and treatments. In December, after the consent of the consent of Congress, NIH formally renounced quota of 10% of the funding.

The results from the NIH's budget request for fiscal year 2017 can be seen. This year, the agency funded AIDS research with the amount of $ 3 billion in 2015 was flat, and is expected to remain at that level in 2017. Since last year's NIH budget grew by nearly 7%, and are demanding a further increase next year's budget, and therefore will be assigned to the portion of AIDS research in 2015 down to 10% this year, 9.3% next year it may be reduced to 9%.